Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic cancer.
Aged
Biomarkers, Tumor
/ genetics
Calcium-Binding Proteins
/ genetics
Female
Follow-Up Studies
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Immunotherapy
/ mortality
Male
Neoplasm Proteins
/ genetics
Pancreatic Neoplasms
/ drug therapy
Prognosis
Survival Rate
Transcriptome
Tumor Microenvironment
Pancreatic cancer
immune cell infiltration
immune-related gene
prognosis
tumor mutation burden
Journal
Bioengineered
ISSN: 2165-5987
Titre abrégé: Bioengineered
Pays: United States
ID NLM: 101581063
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
pubmed:
17
10
2021
medline:
17
2
2022
entrez:
16
10
2021
Statut:
ppublish
Résumé
Pancreatic cancer is associated with a high mortality rate, and the prognosis is positively related to immune status. In this study, we constructed a prognostic signature from survival- and immune-related genes (IRGs) to guide treatment and assess prognosis of patients with pancreatic cancer. The transcriptomic data were obtained from The Cancer Genome Atlas (TCGA) database, and IRGs were extracted from the ImmPort database. Univariate and LASSO regression analysis were used to obtain survival-related IRGs. Finally, the prognostic signature was constructed using multivariate regression analysis. The laboratory experiments were conducted to verify the key IRG expression. Immune cells infiltration was analyzed using the CIBERSORT algorithm and TIMER database. Prognostic signature containing four IRGs (ADA2, TLR1, PTPN6, S100P) was constructed with good predictive performance; in particular, S100P played a significant role in the immune microenvironment, and tumorigenesis of pancreatic cancer. Moreover, we found that CD8
Identifiants
pubmed: 34654352
doi: 10.1080/21655979.2021.1992331
pmc: PMC8806945
doi:
Substances chimiques
Biomarkers, Tumor
0
Calcium-Binding Proteins
0
Neoplasm Proteins
0
S100P protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9006-9020Références
Br J Surg. 2016 Aug;103(9):1189-99
pubmed: 27256393
Front Oncol. 2019 Dec 10;9:1314
pubmed: 31921619
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
J Clin Oncol. 2020 Jan 1;38(1):71-80
pubmed: 31644329
Bioinformatics. 2015 Sep 1;31(17):2912-4
pubmed: 25964631
Biomed Res Int. 2020 Jun 9;2020:1346045
pubmed: 32596278
Int J Mol Sci. 2014 Dec 24;16(1):159-77
pubmed: 25547486
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Ann Oncol. 2019 Jul 1;30(7):1096-1103
pubmed: 31038663
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Nucleic Acids Res. 2003 Jan 1;31(1):258-61
pubmed: 12519996
Trends Cancer. 2018 Jun;4(6):418-428
pubmed: 29860986
Cancer Immunol Res. 2018 Nov;6(11):1364-1374
pubmed: 30201735
Cancer Res. 2017 Nov 1;77(21):e19-e22
pubmed: 29092931
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
J Immunol. 2013 Dec 15;191(12):6178-90
pubmed: 24227786
Cancer Med. 2020 Oct;9(20):7440-7452
pubmed: 32815653
Front Med (Lausanne). 2021 Apr 01;8:649326
pubmed: 33869254
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Cancer Lett. 2017 Oct 28;407:57-65
pubmed: 28826722
J Leukoc Biol. 2010 Aug;88(2):279-90
pubmed: 20453107
Int Immunopharmacol. 2021 Mar;92:107359
pubmed: 33465729
Lancet. 2020 Jun 27;395(10242):2008-2020
pubmed: 32593337
Endocrinology. 1999 Feb;140(2):765-77
pubmed: 9927304
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
Oncol Rep. 2018 Nov;40(5):2608-2618
pubmed: 30226614
Oncologist. 2017 Dec;22(12):1478-1490
pubmed: 28912153
Aging (Albany NY). 2020 Apr 20;12(8):6966-6980
pubmed: 32310824
Bioinformatics. 2019 Oct 15;35(20):4200-4202
pubmed: 30903160
Mol Cancer. 2018 Jul 30;17(1):108
pubmed: 30060755
Virchows Arch. 2018 Apr;472(4):653-665
pubmed: 29356891
Int J Mol Sci. 2019 Sep 11;20(18):
pubmed: 31514451
Hepatobiliary Surg Nutr. 2019 Aug;8(4):345-360
pubmed: 31489304
Cell Cycle. 2016;15(1):25-40
pubmed: 26636629
Int J Mol Med. 2014 Apr;33(4):769-76
pubmed: 24481067
Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8698-E8706
pubmed: 30150374
PLoS One. 2014 Sep 17;9(9):e107468
pubmed: 25229481
Mol Carcinog. 2020 Jul;59(7):775-782
pubmed: 32166821
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Curr Top Microbiol Immunol. 2017;410:191-214
pubmed: 28929190
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Immunol Res. 2014 May;58(2-3):234-9
pubmed: 24791905
Int J Mol Sci. 2019 Aug 30;20(17):
pubmed: 31480292
J Clin Med. 2019 Sep 16;8(9):
pubmed: 31527414
Front Oncol. 2020 Jan 15;9:1533
pubmed: 32010623
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
Front Oncol. 2021 Feb 24;10:618215
pubmed: 33718118
Br J Cancer. 2013 Mar 5;108(4):914-23
pubmed: 23385730
Clin Cancer Res. 2005 Aug 1;11(15):5356-64
pubmed: 16061848
Cancer Lett. 2020 Jan 28;469:142-150
pubmed: 31669518
Ann Rheum Dis. 2020 Feb;79(2):225-231
pubmed: 31707357
Gastroenterology. 2018 Apr;154(5):1494-1508.e13
pubmed: 29248441